Why MNCs Are Doubling Down on Singapore with $570 Million in Biopharma Expansions

On March 15, Novartis' $256 million (approximately 2.4 billion RMB) biopharmaceutical plant expansion project officially broke ground.The expanded factory will focus on producing therapeutic antibody drugs, providing breakthrough treatments for patients worldwide. The expanded facility is expected to begin operations in early 2026. Currently, the factory produces 140 batches annually, equivalent to 9 million finished doses, and after the expansion, its output will more than double.

Less than 60 days ago, on January 25, AbbVie announced an investment of $223 million (approximately 1.6 billion RMB) to expand its production facilities in Singapore.Increase the capacity of its global production network by 24,000 liters of biologic active pharmaceutical ingredients and support AbbVie's existing products as well as emerging immunology and oncology compounds.

In just the first three months of 2024, MNC invested 4 billion yuan in expansion projects in Singapore, all targeted at the biopharmaceutical sector. Notably, both AbbVie and Novartis emphasized in their announcements "providing antibody drugs for Novartis patients worldwide," "serving the global market," and "enhancing the global production network." Behind these significant investments lies an upgrade in MNC’s positioning of its Singapore plant and headquarters.

As the industrial seeds planted by the government grow vigorously, MNCs take on the role of "nurturers," and Singapore's biomedical industry is gradually transforming into a "world manufacturing hub."

Known globally as an international financial hub and a city-state, Singapore has extremely limited land resources. However, what is often overlooked is that Singapore's manufacturing sector contributes significantly to its GDP. As of 2022, the four industries making the largest contributions to Singapore’s GDP were manufacturing (21.6%), wholesale trade (18.6%), financial insurance (13.5%), and transportation and storage (10.4%).

According to the latest 2021 Bloomberg Innovation Index, Singapore ranks second in the world, following South Korea. In terms of manufacturing capabilities, Singapore has risen to third globally, trailing only Ireland and South Korea.

The rapid development of the biopharmaceutical industry is a typical example of Singapore's industrial park strategy. Through the combined effects of the principle of "planning first, then operating," a model that integrates government leadership with market-oriented operations, and an emphasis on the integration of industry, academia, and research, biopharmaceutical industrial parks have become the driving force behind the swift growth of Singapore's biopharmaceutical sector.

Singapore's biomedical industry has formed an industrial cluster pattern with "Tuas Manufacturing" as the industrial foundation and "Biopolis Research and Development" as the innovation source, with a total planned area of 5.8 square kilometers.

Tuas Biomedical Park is the first officially established biomedical industrial park in Singapore, with a core focus on biologics and medical devices, primarily providing facilities for biomedical companies to construct production plants. The park is located in the Tuas area of eastern Singapore, 8 kilometers away from the central one-north tech hub and just a 20-minute drive from Jurong Port, Singapore's only international multi-purpose port, occupying a very advantageous geographical position.In the past two years, the production plants expanded by AbbVie and GlaxoSmithKline have been established here.

Biopolis Life Science Park is located in the heart of Singapore, only a 20-minute drive from the main urban area. Importantly, Biopolis Life Science Park is close to two world-class universities, the National University of Singapore and Nanyang Technological University, housing multiple research institutes and key laboratories in the field of life sciences.In response to the significant demand for the commercialization of large-scale in-campus technologies and patents, Qiaoyuan has fully utilized its role as a platform for technical exchange and sharing, accelerating the process of transforming scientific research achievements from development to clinical application and further commercialization. This has resulted in a complete industrial innovation chain from upstream R&D to downstream development.

In addition, the Singapore government has also establishedNational Science and Technology Research Bureau, promote the connection between industry and academic research, certify industrial projects within the park, provide funding support, coordinate park resources, and help enterprises land smoothly.

It is not difficult to see that convenient transportation, port and transportation advantages, complete policies and supporting facilities, rich talent resources, transformation of scientific research achievements, and a complete innovation chain are all important advantages for the rapid rise of Singapore's biomedicine parks.

But the more crucial point is, in the face of digital and automated factory transformations, as well as the location selection for factories producing new types of products, why are MNCs still willing to continue betting on Singapore?

"Sweet spot" is the first keyword that MNCs continue to bet on.

Taking GSK, the first world-class pharmaceutical company to enter Singapore, as an example, GSK began its layout in the Singapore market as early as the 1970s. Initially, it mainly engaged in simple production and market sales, and gradually expanded its team in Singapore. Relying on the rapid development of Singapore's industrial cluster, GSK’s coverage in the Asian market has continued to expand. To adapt to new development needs, in 2015, GSK officially relocated its Asia-Pacific headquarters to Singapore. Nearly 150 global or regional senior executives were transferred to Singapore to promote faster and more effective decision-making for the company in this region.Analysis points out that the rapid growth in sales in ASEAN's five major economies (including Indonesia and Thailand) has prompted GSK to shift more business operations to Singapore.

GSK, which has tasted the sweetness of development, has made significant moves in Singapore, investing $400 million to establish three manufacturing plants and its first preclinical laboratory. The various active pharmaceutical ingredients produced are mainly used for treating respiratory, oncology, allergy, antiviral, and neurological diseases.

Last July, GSK deepened its investment in Singapore by relocating the production base of active pharmaceutical ingredients for its next-generation hepatitis B vaccine from Europe to Singapore. The company invested SGD 343 million to expand its Tuas vaccine manufacturing plant in Singapore, bringing the total investment to SGD 850 million, making it the largest vaccine production base in Singapore.

The second keyword lies in "partner."

Since 1986, Novartis has established a strong partnership with Singapore. As part of its commitment to Singapore, Novartis has invested over 1 billion US dollars to help "enhance the country's pharmaceutical capabilities." In 2002, Novartis established its first manufacturing base in Singapore. In 2013, Novartis built its first biopharmaceutical production facility in Asia, which also represents one of its largest production investments, carried out with significant support from the Singapore government.

In 2021, Novartis' CAR-T therapy Kymriah was approved for marketing in Singapore, becoming the first commercialized CAR-T cell treatment product in the country. As a personalized therapy, CAR-T requires modifying the patient's own T cells to combat and kill cancer cells. Introducing this innovative therapy to Singapore necessitated collaboration among many healthcare system stakeholders, including regulatory approvals, treatment center evaluations, patient verification, personnel training, and the integration and establishment of an entirely new personalized treatment delivery system.

From this perspective, the "co-construction" based on "partnership" is reshaping and building a new generation of Singapore's biopharmaceutical industry.

Moreover, AbbVie's factory expansion will create more than 100 new jobs in Singapore; Novartis' expanded facility will generate 100 high-skilled new positions, including scientists and engineers. Novartis stated that the company plans to deploy digital and automation solutions at the plant to enhance productivity, operational efficiency, and employee skills. The expanded facility will not only bring in new team members but also provide training for existing employees, enabling them to thrive in a highly digitalized and automated environment.

Analysis points out that many pharmaceutical companies choose Singapore as the starting point for global business development because Singapore has a strong manufacturing base, an efficiently connected transportation and logistics network, ensuring the rapid delivery of biopharmaceutical products. This advantage makes Singapore an ideal operational base to meet the demands of both the Asian and global markets.

For MNCs, the initial layout in Singapore might have been a window to access the Asian, Southeast Asian, and even African markets. To date, Singapore has become a crucial development hub in their global landscape, such as establishing innovation centers targeting the Asia-Pacific, Middle East, and African regions.The deep reason for MNCs' continued investment might be the innovative, mutually supportive, and co-built biopharmaceutical industry ecosystem.

When the industrial iteration wave of digitalization, automation, and AI large models arrives, Singapore's innovative service chain of talent-research-industrial park in the biomedical field has grown into fertile ground that nurtures industrial innovation and sustains the incubation of talent and innovation.

References:

"From 0 to 36.3 Billion USD: The Advancement of Asia's Bio-City" https://www.vbdata.cn/50096

"Singapore's Advanced Manufacturing Development Experience and Insights" https://www.thepaper.cn/newsDetail_forward_23935275